A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry.

Autor:	Ozdemir ZN; Ankara City Hospital, Ankara, Turkey. Electronic address: zehranarli@hotmail.com., Falay M; Duzen Laboratories Group, Ankara, Turkey., Parmaksiz A; Istanbul Health and Technology University, Istanbul, Turkey., Genc E; Ankara City Hospital, Ankara, Turkey., Beyler O; Ankara City Hospital, Ankara, Turkey., Gunes AK; Ankara City Hospital, Ankara, Turkey., Ceran F; Ankara City Hospital, Ankara, Turkey., Dagdas S; Ankara City Hospital, Ankara, Turkey., Ozet G; Yildirim Beyazit University, School of Medicine, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2023 Apr-Jun; Vol. 45 (2), pp. 176-181. Date of Electronic Publication: 2021 Nov 29.
DOI:	10.1016/j.htct.2021.08.012
Abstrakt:	Introduction: The availability of a clinical decision algorithm for diagnosis of chronic lymphocytic leukemia (CLL) may greatly contribute to the diagnosis of CLL, particularly in cases with ambiguous immunophenotypes. Herein we propose a novel differential diagnosis algorithm for the CLL diagnosis using immunophenotyping with flow cytometry. Methods: The hierarchical logistic regression model (Backward LR) was used to build a predictive algorithm for the diagnosis of CLL, differentiated from other lymphoproliferative disorders (LPDs). Results: A total of 302 patients, of whom 220 (72.8%) had CLL and 82 (27.2%), B-cell lymphoproliferative disorders other than CLL, were included in the study. The Backward LR model comprised the variables CD5, CD43, CD81, ROR1, CD23, CD79b, FMC7, sIg and CD200 in the model development process. The weak expression of CD81 and increased intensity of expression in markers CD5, CD23 and CD200 increased the probability of CLL diagnosis, (p < 0.05). The odd ratio for CD5, C23, CD200 and CD81 was 1.088 (1.050 - 1.126), 1.044 (1.012 - 1.077), 1.039 (1.007 - 1.072) and 0.946 (0.921 - 0.970) [95% C.I.], respectively. Our model provided a novel diagnostic algorithm with 95.27% of sensitivity and 91.46% of specificity. The model prediction for 97.3% (214) of 220 patients diagnosed with CLL, was CLL and for 91.5% (75) of 82 patients diagnosed with an LPD other than CLL, was others. The cases were correctly classified as CLL and others with a 95.7% correctness rate. Conclusions: Our model highlighting 4 markers (CD81, CD5, CD23 and CD200) provided high sensitivity and specificity in the CLL diagnosis and in distinguishing of CLL among other LPDs. Competing Interests: Conflicts of interest The authors have no competing interests. (Copyright © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu